» Sign in / Register

AP5A

P1-(5'-Adenosyl) P5-(5'-adenosyl) pentaphosphate, Sodium salt

Product Cat. No. Amount Price (EUR) Buy / Note
AP5A NU-508S 50 μl (10 mM) 118,45 Add to Basket/Quote Add to Notepad
AP5A NU-508L 5 x 50 μl (10 mM) 346,95 Add to Basket/Quote Add to Notepad

Structural formula of AP5A

For research use only!

Shipping: shipped on blue ice

Storage Conditions: store at -20 °C
Short term exposure (up to 1 week cumulative) to ambient temperature possible. If stored as recommended, Jena Bioscience guarantees optimal performance of this product for 12 months after date of delivery.

Shelf Life: 12 months

Molecular Formula: C20H29N10O22P5 (free acid)

Molecular Weight: 916.37 g/mol (free acid)

CAS#: 41708-91-2

Purity: ≥ 95 % (HPLC)

Form: clear aqueous solution, pH 7.5 ±0.5

Concentration: 10 mM - 11 mM

pH: 7.5 ±0.5

Spectroscopic Properties: λmax 259 nm; ε 27.0 L mmol-1 cm-1 (Tris-HCl pH 7.5)

Specific Ligands:

Ligand for P2Y and P2X receptors:
Agonist at P2Y1 receptor[1,2,3], at P2X1 receptor[4,5], P2X1 - P2X4, P2Y1,2,4,12 receptors[2,4,5] and vascular purinoreceptor P2X[6]

Selected References:
[1] Gualix et al. (2014) Presence of diadenosine polyphosphates in microdialysis samples from rat cerebellum in vivo: effect of mild hyperammonemia on their receptors. Purinergic Signal. 10 (2):349.
[2] Szczepanska-Konkel et al. (2005) Effects of diadenosine polyphosphates on glomerular volume. Br. J. Pharmacol. 144 (8):1109.
[3] Yerxa et al. (2001) P1- (uridine 5')-P4- (2'-deoxycytidine 5')tetraphosphate tetrasodiumsalt a next generation P2Y2 receptor agonist for treatment of cystic fibrosis. J. Pharmacol. Exp. Ther. 302:871.
[4] Zhang et al. (2002) Identification and characterization of a novel Gαi-coupled ADP receptor from human and mouse. J. Pharmacol. Exp. Ther. 301 (2):705.
[5] Allsopp et al. (2013) P2X receptor chimeras highlight roles of amino terminus to partial agonist efficacy, the carboxyl terminus to recovery from desentization, and independent regulation of channel transitions. J. Biol. Chem. 288 (29):21412.
[6] Neely et al. (1996) P2X purinoreceptors in the feline pulmonary vascular bed: distribution and selective in vivo pharmacological probes. Am. J. Physiol. 270 (6 Pt 1):L889.
Pintor et al. (1999) Presence of dinucleotide and ATP receptors in human cerebrocortical synaptic terminals. Eur. J. Pharmacol. 366:159.
Wildman et al. (1999) Selectivity of diadenosine polyphosphates for rat P2X receptor subunits. Eur. J. Pharmacol. 367:119.
Jovanovic et al. (1998) Diadenosine 5',5''-P1,P5-pentaphosphate harbors the properties of a signaling molecule in the heart. FEBS Lett. 423:314.
Verspohl et al. (1998) Diadenosine polyphosphates in insulin-secreting cells: interaction with specific receptors and degradation. Diabetes 47:1727.
Delaney et al. (1997) Diadenosine polyphosphates inhibit adenosine kinase activity but decrease levels of endogenous adenosine in rat brain. Eur. J. Pharmacol. 332:35.
Edgecombe et al. (1997) Diadenosine polyphosphate-stimulated gluconeogenesis in isolated rat proximal tubules. Biochem. J. 323:451.
Ogilvie et al. (1996) Adenine dinucleotides: a novel class of signalling molecules. J. Auton. Pharmacol. 16:325.
Schluter et al. (1994) Diadenosine phosphates and the physiological control of blood pressure. Nature 367:186.